

Mangalam Drugs and Organics Ltd.

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
Phone : 91-22-22616200 / 6300 / 8787 • Fax : 91-22-22619090 • CIN : L24230MH1972PLC116413



01st August, 2016

To
DCS-CRD
The Secretary
Bombay Stock Exchange
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

To,
**National Stock Exchange of India
Limited**
“Exchange Plaza”,
Bandra - Kurla Complex,
Bandra(E), Mumbai – 400 051

Sub: Unaudited Financial Results for the Quarter ended on 30th June, 2016

Scrip Code: 532637
Symbol: MANGALAM

Dear Sir,

In terms of Regulation 33 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Unaudited Financial Results for the quarter ended 30th June, 2016 along with the Limited Review Report of the said period in the prescribed form which have been taken on record by the Board of Directors of the Company at its meeting held on 01st August, 2016 at Mumbai.

Kindly note that the meeting of the Board of Directors commenced at 11.30 a.m and concluded at 1.15 p.m.

Further please note that the company has made necessary arrangement to publish the same in the newspaper as required under the Listing Regulations.

Kindly take the same in your records.

Thanking You,
Yours faithfully,
For **Mangalam Drugs & Organics Ltd**

Nikita Bavishi
Nikita Bavishi
Company Secretary.



Works: at Vapi (Gujarat) India • E-Mail : contactus@mangalamdrugs.com • Website : <http://www.mangalamdrugs.com>

Un-Audited Financial Results for the Quarter ended 30th June 2016 approved and taken on record by the Board at their meeting dated 01st August 2016

(Rs. in Lacs)

Sr. No.	Particulars	3 Months ended 30.06.2016 (Unaudited)	Corresponding 3 months ended 30.06.2015 (Unaudited)	3 Months ended 31.03.2016 (Audited)	Year Ended 31.03.2016 (Audited)
A PART I - STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2016					
1	Sales/Income from operation(Net of Excise duty)	6697.20	6956.09	7055.06	29502.18
2	Other Operating Income	1.30	2.72	11.17	13.89
3	Total Net Income from Operation	6698.50	6958.81	7066.23	29516.07
4	Expenditure				
	(a) Increase / decrease in stock in trade & work in progress	674.81	751.76	(417.77)	(7.95)
	(b) Consumption of raw materials	3756.19	4376.72	4461.42	20185.07
	(c) Employees Cost	402.87	304.75	410.23	1434.87
	(d) Depreciation	96.69	108.25	108.62	441.30
	(e) Other expenditure	833.54	880.23	1177.55	4134.02
	(f) Total	5764.10	6421.71	5740.05	26187.31
	Profit(+)/Loss(-) from operations before Other income, Finance cost and Exceptional Items(3-4)	934.40	537.10	1326.18	3328.76
6	Other income	0.82	70.55	(72.41)	2.02
7	Profit (+) / Loss (-) from ordinary activities before Finance Cost & Exceptional Items(5+6)	935.22	607.65	1253.77	3330.78
8	Finance Cost	229.97	232.39	277.03	929.18
	Profit(+)/Loss(-) from ordinary activities after Finance cost & Exceptional Items(7-8)	705.25	375.26	976.74	2401.60
10	Exceptional Items	0.00	0.00	0.00	0.00
11	Profit(+)/Loss(-) before Tax (9-10)	705.25	375.26	976.74	2401.60
12	Tax Expenses(incl Deferred Tax)	195.00	70.00	423.29	798.29
13	Net Profit(+)/Loss(-) after Tax (11-12)	510.25	305.26	553.45	1603.31
14	Extraordinary Items	0.00	0.00	0.00	0.00
15	Net Profit(+)/Loss(-) for the period(13-14)	510.25	305.26	553.45	1603.31
16	Paid up Equity Share Capital (face value Rs.10/-each)	1582.82	1317.82	1437.82	1437.82
17	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.	0.00	0.00	3897.44	3897.44
18 (i)	Earning per share (EPS)(before extraordinary items)(of Rs 10/- each)(not annualised)				
	(a) Basic	3.22	2.32	3.85	11.15
	(b) Diluted	3.22	2.32	3.50	10.13
18 (ii)	Earning per share (EPS)(after extraordinary items)(of Rs 10/- each)(not annualised)				
	(a) Basic	3.22	2.32	3.85	11.15
	(b) Diluted	3.22	2.32	3.50	10.13
16	Investors Complaints :	3 Months ended 30.06.2016			
	Pending at the Beginning of the Quarter	Nil			
	Received during the Quarter	Nil			
	Disposed of during the Quarter	Nil			
	Remaining unresolved at the end of the Quarter	Nil			

Notes:

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 1st August, 2016
- The above results have been subjected to limited review by Statutory Auditors.
- 14,50,000 Equity shares are allotted on 10/06/2016 pursuant to conversion of 14,50,000 Share Warrants which were allotted on 28/09/2015.
- As the Company's business activity falls within a single primary business segment viz "Manufacturing of Bulk Drugs" the disclosure requirements of Accounting Standard(AS-17) "Segment Reporting" is not applicable
- The CEO & CFO have certified that the Un-audited Financial Results for the Quarter ended 30th June 2016 do not contain any false or misleading statements or figures and do not omit any material facts which may make the statements or figures therein misleading.
- Previous year figures are regrouped wherever necessary.

Place: Mumbai
Date: 01.08.2016


For MILWANI ASSOCIATES
Chartered Accountants



(CA) Rakesh V. Milwani) Proprietor
Membership No.: 36099
F.R.N.:106405W

On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd

(Shri Govardhan M. Dhoot)
Managing Director
DIN:01240086



18, Bagaria House, 1st Floor, 31/33, Dr. M.B. Velkar Lane, Mumbai - 400 002.
Tel. : 22036132/9821162679 E-mail: rakesh_milwani@hotmail.com

Limited Review Report

Review Report to
The Board of Directors
Mangalam Drugs & Organics Limited

We have reviewed the accompanying statement of unaudited financial results of **Mangalam Drugs & Organics Limited** for the period ended **30th June, 2016**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place of signature: Mumbai
Date: 1st August, 2016.

For Milwani Associates
Chartered Accountants



RAKESH K MILWANI
Proprietor
Membership Number. 36099
Firm Reg No. 106405W